These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30107489)

  • 41. The Association of Clustered Ventricular Arrhythmia and Cycle Length With Scar Burden in Cardiomyopathy.
    Vakil RM; Marine JE; Kolandaivelu A; Dickfeld T; Weiss RG; Tomaselli GF; Chrispin J; Wu KC
    JACC Clin Electrophysiol; 2022 Aug; 8(8):957-966. PubMed ID: 35981800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy.
    Higgins AY; Annapureddy AR; Wang Y; Minges KE; Bellumkonda L; Lampert R; Rosenfeld LE; Jacoby DL; Curtis JP; Miller EJ; Freeman JV
    Am Heart J; 2022 Apr; 246():21-31. PubMed ID: 34968442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators.
    Scott PA; Morgan JM; Carroll N; Murday DC; Roberts PR; Peebles CR; Harden SP; Curzen NP
    Circ Arrhythm Electrophysiol; 2011 Jun; 4(3):324-30. PubMed ID: 21493964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Pathak RK; Sanders P; Deo R
    Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure.
    Biton Y; Rosero S; Moss A; Zareba W; Kutyifa V; Baman J; Barsheshet A; McNitt S; Polonsky B; Goldenberg I
    Am J Cardiol; 2018 Mar; 121(5):615-620. PubMed ID: 29307459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction.
    van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP
    Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two-Year Outcomes of Primary Prophylactic Use of Defibrillators for Ischemic and Non-Ischemic Cardiomyopathy　- Propensity Score-Matched Analysis From the Nippon Storm Study.
    Kondo Y; Noda T; Takanashi Y; Sasaki S; Sato Y; Nitta T; Aizwa Y; Ohe T; Kurita T
    Circ J; 2024 Jun; 88(7):1107-1114. PubMed ID: 38057099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of T wave amplitude in lead aVR on predicting cardiac events in ischemic and nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator.
    Tanaka Y; Konno T; Tamura Y; Tsuda T; Furusho H; Takamura M; Sakata K; Yamagishi M; Hayashi K
    Ann Noninvasive Electrocardiol; 2017 Nov; 22(6):. PubMed ID: 28440568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cluster Randomized Trial Examining the Impact of Automated Best Practice Alert on Rates of Implantable Defibrillator Therapy.
    Lee J; Szeto L; Pasupula DK; Hussain A; Waheed A; Adhikari S; Sharbaugh M; Thoma F; Althouse AD; Fischer G; Lee JS; Saba S
    Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005024. PubMed ID: 31181957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
    Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
    Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overweight and obesity as protective factors against mortality in nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator.
    Zhou B; Zhao S; Tang M; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Li X; Xue X; Sun X; Zhang S
    Clin Cardiol; 2020 Dec; 43(12):1435-1442. PubMed ID: 32936479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
    Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
    Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D
    J Am Coll Cardiol; 2018 Oct; 72(14):1653-1676. PubMed ID: 29097297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term predictors of mortality in ICD patients with non-ischaemic cardiac disease: impact of renal function.
    Schefer T; Wolber T; Binggeli C; Holzmeister J; Brunckhorst C; Duru F
    Europace; 2008 Sep; 10(9):1052-9. PubMed ID: 18687703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.
    Greulich S; Deluigi CC; Gloekler S; Wahl A; Zürn C; Kramer U; Nothnagel D; Bültel H; Schumm J; Grün S; Ong P; Wagner A; Schneider S; Nassenstein K; Gawaz M; Sechtem U; Bruder O; Mahrholdt H
    JACC Cardiovasc Imaging; 2013 Apr; 6(4):501-11. PubMed ID: 23498675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry.
    Guaricci AI; Masci PG; Muscogiuri G; Guglielmo M; Baggiano A; Fusini L; Lorenzoni V; Martini C; Andreini D; Pavon AG; Aquaro GD; Barison A; Todiere G; Rabbat MG; Tat E; Raineri C; Valentini A; Varga-Szemes A; Schoepf UJ; De Cecco CN; Bogaert J; Dobrovie M; Symons R; Focardi M; Gismondi A; Lozano-Torres J; Rodriguez-Palomares JF; Lanzillo C; Di Roma M; Moro C; Di Giovine G; Margonato D; De Lazzari M; Perazzolo Marra M; Nese A; Casavecchia G; Gravina M; Marzo F; Carigi S; Pica S; Lombardi M; Censi S; Squeri A; Palumbo A; Gaibazzi N; Camastra G; Sbarbati S; Pedrotti P; Masi A; Carrabba N; Pradella S; Timpani M; Cicala G; Presicci C; Puglisi S; Sverzellati N; Santobuono VE; Pepi M; Schwitter J; Pontone G
    Europace; 2021 Jul; 23(7):1072-1083. PubMed ID: 33792661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.